3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
50
Lymphoma, Non-Hodgkin
45
Lymphoma
34
Lymphoma, Mantle-Cell
30
Lymphoma, Follicular
26
Multiple Myeloma
23
Hodgkin Disease
21
Lymphoma, Large B-Cell, Diffuse
18
Recurrence
13
Lymphoma, B-Cell, Marginal Zone
12
Leukemia
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Neoplasms
6
Lymphoma, T-Cell
5
Waldenstrom Macroglobulinemia
4
Lymphoma, Large-Cell, Anaplastic
4
Lymphoma, B-Cell
4
Leukemia, Myeloid, Acute
4
Leukemia, B-Cell
4
Breast Neoplasms
4
Small Cell Lung Carcinoma
3
Sezary Syndrome
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Neoplasms, Plasma Cell
3
Myelodysplastic Syndromes
3
Mycosis Fungoides
3
Lymphoma, T-Cell, Peripheral
3
Lymphoma, T-Cell, Cutaneous
3
Lymphoma, Extranodal NK-T-Cell
3
Immunoblastic Lymphadenopathy
3
Interventions
pembrolizumab
125
Cisplatin
28
Carboplatin
25
lenvatinib
24
Paclitaxel
20
Docetaxel
16
Fluorouracil
13
Pemetrexed
11
Capecitabine
11
Gemcitabine
10
Saline Solution
8
Oxaliplatin
8
epacadostat
6
Leucovorin
5
Irinotecan
5
Cetuximab
5
Albumin-Bound Paclitaxel
5
130-nm albumin-bound paclitaxel
5
olaparib
4
Bevacizumab
4
trifluridine tipiracil drug combination
3
regorafenib
3
enzalutamide
3
durvalumab
3
Nivolumab
3
Etoposide
3
trametinib
2
etoposide phosphate
2
dabrafenib
2
Tretinoin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Bendamustine Hydrochloride
×
Clear all
NCT05508867
2026-01-20
MK-4280A-008
Merck Sharp & Dohme LLC
Phase 2
Completed
203 enrolled